Biovail Acquires Ativan and Isordil from Wyeth.

Canadian Corporate News, June, 2003

TORONTO, ONTARIO, Jun 2, 2003 (CCNMatthews via COMTEX)

-- Anxiety treatment Ativan complements Biovail's growing CNS franchise

-- Isordil further expands Biovail's cardiovascular product line

Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has acquired U.S. rights to the Ativan(R) (lorazepam) and Isordil(R) (isosorbide dinitrate) oral product lines from Wyeth (NYSE:WYE) for $130 million and annual payments pursuant to a three year supply agreement. Sales of Ativan and Isordil in the U.S. were in excess of $50 million in 2002.

Ativan is a benzodiazepine, ...